Icoria, a provider and developer of a variety of biotechnology services, has signed a licensing deal with Syngenta that will bring the RTP firm an undisclosed amount of cash.

Icoira (Nasdaq: ICOR) said the deal includes rights to 30 compounds that could be active fungal inhibitors.

Icoria said it will receive a “modest upfront payment” as well as milestones and royalties should Syngenta move to commercialize any of the compounds. Icoria said the compounds could have agricultural as well as human applications.

Icoria: www.icoira.com